Ang II/AT1R was determined to promote NAFLD, and previous studies have illustrated that AT1R blockade can ameliorate fatty liver and that AT1R blockers can potentially be used for NAFLD therapy11,12. Here, AGT is linked to metabolic dysfunction-associated steatotic liver disease.